Here below are the publications (5) participated by Francesco Bertoni along with Marilia Barreca (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).
Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch
1) The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
Francesco Bertoniis currently collaborating with
Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5
6500 Bellinzona
Francesco Bertoni
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Lymphoma Genomics
as Group Leader [Rif. 55110]
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Lymphoma Genomics
as Group Leader [Rif. 55110]
Francesco Bertoni
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently Research Program Leader [Rif. 50110] for
Lymphoma and Genomics (Rif. 20000 2023)
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently Research Program Leader [Rif. 50110] for
Lymphoma and Genomics (Rif. 20000 2023)